top of page
News & Updates
Press Release: Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
New York, NY August 13, 2025 – Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing deals with Galibra Neuroscience and Emugen Therapeutics to utilize Apertura’s human transferrin receptor 1 capsid (TfR1 CapX) for their central nervous system (CNS) programs.
Aug 13
bottom of page